Search Results - "Simonian, Nancy A."

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis by Jacobs, Lawrence D, Beck, Roy W, Simon, Jack H, Kinkel, R. Phillip, Brownscheidle, Carol M, Murray, Thomas J, Simonian, Nancy A, Slasor, Peter J, Sandrock, Alfred W

“…Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system that most commonly affects women, with an onset typically…”
Get full text

Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation by Simonian, N A, Hyman, B T

“…The activity of cytochrome oxidase (CO), the terminal enzyme of the electron transport chain, has been reported to be decreased in the brains of individuals…”
Get more information

Functional alterations in Alzheimer's disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone by Harr, S D, Simonian, N A, Hyman, B T

“…Positron emission tomography (PET) studies measuring glucose utilization have demonstrated cerebral hypometabolism in Alzheimer's disease (AD). The anatomic…”
Get more information

Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation by Simonian, N A, Hyman, B T

“…In Alzheimer's disease, the relationship between structural alterations such as neurofibrillary tangles and senile plaques and neuronal function is unknown…”
Get more information

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial by Cohen, J A, Cutter, G R, Fischer, J S, Goodman, A D, Heidenreich, F R, Jak, A J, Kniker, J E, Kooijmans, M F, Lull, J M, Sandrock, A W, Simon, J H, Simonian, N A, Whitaker, J N

“…The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation…”
Get more information

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis by Rudick, Richard A., Cookfair, Diane L., Simonian, Nancy A., Ransohoff, Richard M., Richert, John R., Jacobs, Lawrence D., Herndon, Robert M., Salazar, Andres M., Fischer, Jill S., Granger, Carl V., Goodkin, Donald E., Simon, Jack H., Bartoszak, David M., Bourdette, Dennis N., Braiman, Jonathan, Brownscheidle, Carol M., Coats, Michael E., Cohan, Stanley L., Dougherty, David S., Kinkel, Revere P., Mass, Michele K., Munchsauer, Frederick E., O'Reilly, Kathy, Priore, Roger L., Pullicino, Patrick M., Scherokman, Barbara J., Wende, Karl, Weinstock-Guttman, Bianca, Whitham, Ruth H.

“…Background and objective: This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a…”
Get full text

Diazepam‐sensitive encephalopathy by Simonian, Nancy A., Gilliam, Frank G., Chiappa, Keith H.

Get full text

Ifosfamide causes a diazepam-sensitive encephalopathy by Simonian, N A, Gilliam, F G, Chiappa, K H

“…An encephalopathy characterized by confusion, stupor, and mutism frequently occurs during administration of the chemotherapeutic drug ifosfamide (IFX). We…”
Get full text

Functional alterations in neural circuits in Alzheimer's disease by Simonian, Nancy A., Hyman, Bradley T.

“…While a correlation exists at the regional level between the distribution of neurofibrillary tangles and the predicted sites of brain dysfunction based on…”
Get full text

“Summary measure” statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis by SIMONIAN, NANCY A, MCALLISTER, ARTHUR, LULL, JULIA

“…From a clinical perspective, the question should be raised, "Do we want to consider the disability of these patients to be the same by using the AUC summary…”
Get full text

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration by Rogge, Mark C., Simonian, Nancy A., Jones, Wendy E.

Get full text

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis1Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc.1 by Rudick, Richard A., Cookfair, Diane L., Simonian, Nancy A., Ransohoff, Richard M., Richert, John R., Jacobs, Lawrence D., Herndon, Robert M., Salazar, Andres M., Fischer, Jill S., Granger, Carl V., Goodkin, Donald E., Simon, Jack H., Bartoszak, David M., Bourdette, Dennis N., Braiman, Jonathan, Brownscheidle, Carol M., Coats, Michael E., Cohan, Stanley L., Dougherty, David S., Kinkel, Revere P., Mass, Michele K., Munchsauer, Frederick E., O'Reilly, Kathy, Priore, Roger L., Pullicino, Patrick M., Scherokman, Barbara J., Wende, Karl, Weinstock-Guttman, Bianca, Whitham, Ruth H.

Get full text

Functional integrity of neural systems related to memory in Alzheimer's disease by Simonian, N A, Rebeck, G W, Hyman, B T

Get more information

Specific infection of central nervous system white matter by a variant of gross murine leukemia virus by Simonian, N A, Rosenthal, L A, Korostoff, J, Hickey, W F, Blank, K J, Gaulton, G N

“…Exposure of neonatal Balb.B mice to a variant of Gross murine leukemia virus, termed WB91-GV, resulted in selective white matter infection within the central…”
Get more information